Replies to post #402925 on Anavex Life Sciences Corp (AVXL)

[crescentmotor]

I hope it [Simufilam] works but the results so far, while good in aggregate, have been trending down and down with every data release.

Keep in mind that some earlier patients in the first cohort had their spinal fluid examined for specific biomarkers indicating AD. Later patients had no such screening. Nevertheless, the twelve-month data (which did trend down) was significantly better than what would have been historically seen in a twelve-month placebo group. Also, it is important also to note that the results include moderate AD patients which brought the overall scores down.

Finally, the ongoing CMS study and Simufilam's two Phase III trials have tightened eligibility requirements including patients that have already completed a one-year course of Simufilam and elected to remain on the drug. Whey would patients commit to yet an additional year on the drug if they weren't seeing any benefit during the first year?

From my perspective, both AVXL and SAVA have good prospects to eventually gain regulatory approval in the AD space and I retain a 50/50 weighting in both companies for the time being.